Yet, family understanding is important in cases where early
treatment holds the potential for rehabilitation.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in
treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and
potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory
held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«The abstracts we presented at WCLC are prime examples of how our growing body of research and studies at CTCA at Western are advancing medicine and
hold the
potential to provide patients with better cancer
treatments,» Dr. Weiss said.
«These models
hold great
potential for discovery of new
treatments for this paralysis,» Mansfield said.
But if they
hold true, they could point toward a better understanding of the disease and
potential new
treatment strategies.
«Our work not only
holds potential for developing cells for
treatment of other areas of the eye, but could set the stage for future human clinical trials of anterior eye transplantation to restore visual function.»
«Given depression's association with adverse health outcomes in this patient population, including mental health
treatment in primary care
holds potential to improve addiction
treatment outcomes,» Walley said.
A study led by a researcher from Plymouth University in the UK, has discovered that the inhibition of a particular mitochondrial fission protein could
hold the key to
potential treatment for Parkinson's Disease (PD).
This field, the AAMC communication says,
holds «enormous
potential for the
treatment of many diseases» and should be allowed to move forward.
The ability to create sensory interneurons with a patient's own reprogrammed cells
holds significant
potential for the creation of a cell - based
treatment that restores the sense of touch without immune suppression.
Another
potential, says Chan, is «the promise a nonhuman primate model
holds for developing
treatments that could alter the course of Huntington's disease.
With cellular therapy
holding enormous promise for future cures and
treatments, Black Beret Life Sciences is committed to doing what it can to help the field reach its full medical
potential by creating a more efficient regulatory framework in the U.S.
But as they begin to take greater
hold, concerns are rising about the dangers of a
potential black market for the
treatment.»
Longevica Pharmaceuticals, Inc., is a privately
held health - related technology company that is developing novel, proprietary drugs with
potential use in the
treatment of cancer, degenerative diseases and age - related disorders.
We believe that our unique approach to targeting misfolded proteins
holds great
potential to transform the lives of patients suffering from devastating neurodegenerative diseases, who currently have no effective, disease - modifying
treatment options.»
For those patients who suffer from heart failure symptoms with no other option for
treatment, stem cell therapy
holds the
potential to provide a better quality of life.
Thus, the lab's approach may
hold great promise for
potential treatment of (neuro) inflammation - related human diseases both in and outside the central nervous system.
We are excited to evaluate our technology in combination with pembrolizumab as a
potential treatment for lung cancer, and about the promise it may
hold for patients,» said Turnstone CEO Sammy Farah, PhD.
«The surge in cancer immunotherapy research and clinical trials has resulted in an unprecedented flood of data about patient responses to immune - based
treatment, and we believe these data
hold the key to unlocking the full
potential of this
treatment modality for more and eventually all cancer patients,» said Jill O'Donnell - Tormey, Ph.D., CEO and director of scientific affairs at the Cancer Research Institute.
When space allows, we
hold strays for the required 5 days prior to providing any
treatment (unless it's a medical emergency) or processing the pet for
potential adoption.
The meeting,
held August 25 in Atlanta, Ga., explored the
potential relationships between resistance to heartworm products and veterinary and pet owner compliance, loss of product efficacy, and effective heartworm testing and
treatment protocols.
Today, of course, we face more complex challenges than we have ever faced before: a medical system that
holds the promise of unlocking new cures and
treatments — attached to a health care system that
holds the
potential for bankruptcy to families and businesses; a system of energy that powers our economy, but simultaneously endangers our planet; threats to our security that seek to exploit the very interconnectedness and openness so essential to our prosperity; and challenges in a global marketplace which links the derivative trader on Wall Street to the homeowner on Main Street, the office worker in America to the factory worker in China — a marketplace in which we all share in opportunity, but also in crisis.
They believe science
holds the key to defeating dementia, so the research we fund is focused on the causes, care, prevention and
potential treatments for dementia.
At the AMA's national conference in Brisbane, doctors voted to ramp up the political pressure around climate change, and they passed an urgency motion requesting the government to review the Border Force Act, which they said had the
potential to gag doctors from speaking out about the
treatment of refugees being
held in detention centres.
First, Dr. Johnson, a developer of EFT,
held monthly supervision meetings with participating therapists to address
potential impediments to EFT
treatment manual adherence.